2023年4月17日

닫기胃腸道細胞獲得了批準第一階段印第安納州(試驗性新藥)同種異體NK細胞療法。該公司還將推動其與免疫療法聯合政府候選人物質的附屬,胃腸道的創新。GI創新主席Chang Myeong-ho(左)和胃腸道細胞CEO香港Cheon-pyo胃腸道細胞周一說,它已獲得批準1期臨床試驗的同種異體NK細胞療法,新加坡政府投資公司- 102 (T.O.P. NK)的食品和藥物安全。大型醫療機構,包括安南韓國大學醫院,首爾國立大學醫院,峨山醫療中心,上半年將進行臨床試驗開始。在第一階段的臨床試驗,胃腸道細胞計劃確認安全,耐藥性,藥物動力學/藥效學的新加坡政府投資公司- 1023進步的堅實的癌症患者,複發/難治性非霍奇金淋巴瘤和多發性骨髓瘤。根據胃腸道細胞,新加坡政府投資公司- 102是下一代NK細胞療法,最大化和癌症腫瘤功能為輔,效率。與高純度的大眾文化也可能使用免疫細胞純膨脹機,胃腸道細胞對大眾文化的免疫細胞的技術。胃腸道細胞已被證明gic - 102的功效不同固體癌症通過非臨床試驗使用一個人性化的鼠標,尤其是一貫cancer-growth-suppressing功效與各種類型的鼠標移植結腸直腸癌細胞係。在1期臨床試驗中,胃腸道細胞將評估不僅gic的政府——僅102年還與GI聯合政府創新的雙重融合蛋白,GI - 101。gi - 101,半期臨床試驗正在進行中,是一個融合蛋白的目標免疫細胞和IL-2v CD80,一個變化,克服的缺點- 2 - 2。 “GI-101 proliferates and activates NK cells by uniquely binding to receptors expressed in NK cells and is expected to show superior synergy in various solid cancers, including colorectal cancer, through a combined therapy with T.O.P. NK,” said GI Innovation Chairman Chang Myeong-ho said. “NK cells activated by GI-101 induce the expression of chemokine receptors that help smooth infiltration into tumor cells.” GI Cell CEO Hong Cheon-pyo said, “We have moved one step closer to our goal of providing a new treatment option for patients who do not respond to standard treatments. The combined therapy of T.O.P. NK and GI-101 has shown unparalleled durability and efficacy, so we will go all out to win approval as soon as possible by proving their efficacy in clinical trials.” GI Cell said it has a GMP facility of 3,300 square meters to manufacture and supply clinical samples independently. Besides, the company has won permits to manufacture high-technology biopharmaceutical products and to manage human cells and aims to get permission for a cell disposal facility within the first half of this year.